Medpace (NASDAQ:MEDP – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27, FiscalAI reports. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.53 million. Medpace updated its FY 2026 guidance to 17.250-17.950 EPS.
Medpace Stock Performance
Shares of MEDP stock traded down $3.55 on Wednesday, hitting $528.12. 519,626 shares of the stock traded hands, compared to its average volume of 352,461. Medpace has a twelve month low of $373.00 and a twelve month high of $628.92. The firm’s 50-day moving average price is $482.55 and its two-hundred day moving average price is $493.73. The stock has a market capitalization of $15.08 billion, a PE ratio of 33.19, a PEG ratio of 2.64 and a beta of 1.15.
Insider Transactions at Medpace
In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.
Institutional Trading of Medpace
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada reduced their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $547.00 price objective (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, BMO Capital Markets lowered their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $469.50.
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
- Five stocks we like better than Medpace
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
